Triple
T6003725
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Loxo Oncology |
E133655
|
entity |
| Predicate | developedDrug |
P73
|
FINISHED |
| Object |
LOXO-305
LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
|
E566975
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69c00872444c8190bfaf1739dcec765c |
elicitation | completed |
| NER | batch_69c0560bae148190ad4755defaaf471b |
ner | completed |
| NED1 | batch_69c11cdec5608190ad093a09acd32ebf |
ned_source_triple | completed |
| NED2 | batch_69c11e76f5c48190adabb10472729cb2 |
ned_description | completed |
| NEDg | batch_69c11d9102648190a61e9a85ead0fff4 |
nedg | completed |
Created at: March 22, 2026, 4:06 p.m.